- Home
- ANAB vs ASM Comparison
ANAB vs ASM Comparison
Compare ANAB & ASM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | ASM |
|---|---|---|
| Founded | 2005 | 1968 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2015 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ANAB | ASM |
|---|---|---|
| Price | $60.37 | $6.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $71.67 | $8.18 |
| AVG Volume (30 Days) | 586.1K | ★ 4.6M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | N/A | $53.35 |
| Revenue Next Year | $52.14 | $34.26 |
| P/E Ratio | ★ N/A | $67.93 |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $17.11 | $2.85 |
| 52 Week High | $73.30 | $11.99 |
Technical Indicators
Market Signals| Indicator | ANAB | ASM |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 45.87 |
| Support Level | $53.46 | $5.92 |
| Resistance Level | $67.69 | $8.12 |
| Average True Range (ATR) | 4.38 | 0.46 |
| MACD | -0.93 | -0.03 |
| Stochastic Oscillator | 19.86 | 24.62 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.